• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cellectar Biosciences Inc.

    5/28/26 5:14:34 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLRB alert in real time by email
    DEFA14A 1 tm261621d6_defa14a.htm DEFA14A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

     

    Filed by the Registrant x
     
    Filed by a party other than the Registrant ¨

     

    Check the appropriate box:
     
    ¨ Preliminary Proxy Statement
       
      Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    CELLECTAR BIOSCIENCES, INC.

    (Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    GRAPHIC

    NAME & ADDRESS HERE STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the stockholders of record as of May 19, 2026 of Cellectar Biosciences, Inc.: The 2026 Annual Meeting of Stockholders of Cellectar Biosciences, Inc., will be held virtually on July 7, 2026 at 10:00 a.m. Eastern Time. As a registered holder, you may attend and vote your shares at the virtual Annual Meeting by registering at https://web.viewproxy.com/clrb/2026 and using the Control Number above. Your registration must be received by 11:59 p.m. Eastern Time on July 6, 2026. On the day of the Annual Meeting, if you have properly registered, you may log in using the password you received via email in your registration confirmation and follow the instructions to vote your shares. Please have your Control Number with you during the Annual Meeting in order to vote. Further instructions on how to attend and vote during the Annual Meeting are contained in the Proxy Statement in the section titled “About the Annual Meeting.” The Board recommends a vote “FOR” the nominees listed in Proposal 1 and “FOR” Proposals 2, 3, 4, 5 and 6. 1. To vote upon the election of two Class III directors; 01. Andrew Gu 02. Douglas J. Swirsky 2. To approve an increase in the number of shares of common stock available for issuance under our 2021 Stock Incentive Plan; 3. To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; 4. To approve, on a non-binding advisory basis, named executive officer compensation; 5. To approve the exercise of warrants issued by the Company to purchase up to an aggregate of 39,618,078 shares of common stock under applicable rules and regulations of the Nasdaq Stock Market LLC (the “Warrant Exercise Proposal”); and 6. To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the Warrant Exercise Proposal. NOTE: The Board will transact such other business as may properly come before the meeting as determined in the discretion of the proxies. Important Notice Regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held virtually on July 7, 2026 at 10:00 a.m. Eastern Time. This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice, Proxy Statement, and Annual Report are available at https://web.viewproxy.com/clrb/2026 If you want to receive a paper or email copy of these documents, you must request one by following the instructions on the reverse side of this Notice on or before June 30, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the Internet availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e-mail copies of your proxy materials are outlined in this Notice. You must use the 11-digit Control Number located in the box to attend the Annual Meeting virtually, to vote via Internet, or to request proxy materials. CONTROL NUMBER

    GRAPHIC

    The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. CONTROL NUMBER Materials for this Annual Meeting and future meetings may be requested by one of the following methods: Internet Go to https://web.viewproxy.com/clrb/2026. Have the 11-digit Control Number available when you access the website and follow the instructions. E-Mail By e-mail at: requests@viewproxy.com * If requesting material by e-mail, please send a blank e-mail with the company name and your 11-digit Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this email request. Telephone Call 1-877-777-2857 Toll Free VOTING METHODS Via Internet prior to the Annual Meeting: Go to www.fcrvote.com/CLRB Have your 11-digit Control Number available and follow the prompts. • Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Internet during the Annual Meeting: Go to www.fcrvote.com/CLRB Have your 11-digit Control Number available and follow the prompts.

    Get the next $CLRB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLRB

    DatePrice TargetRatingAnalyst
    5/15/2026$10.00Buy
    Ladenburg Thalmann
    3/10/2026$10.00Hold → Buy
    Maxim Group
    12/5/2024$13.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $CLRB
    SEC Filings

    View All

    SEC Form 424B3 filed by Cellectar Biosciences Inc.

    424B3 - Cellectar Biosciences, Inc. (0001279704) (Filer)

    6/2/26 6:01:40 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Cellectar Biosciences Inc.

    EFFECT - Cellectar Biosciences, Inc. (0001279704) (Filer)

    6/2/26 12:15:13 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-1/A filed by Cellectar Biosciences Inc.

    S-1/A - Cellectar Biosciences, Inc. (0001279704) (Filer)

    5/29/26 8:50:22 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Longcor Jarrod bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 74% to 20,451 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    5/11/26 8:07:18 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Caruso James V bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 75% to 20,318 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    5/11/26 8:05:44 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Caruso James V bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 611% to 11,638 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    7/3/25 8:02:08 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

    Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 Confirmatory Clinical Trial in 4Q26 FLORHAM PARK, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inhibitor (BTKi) therapy in the Company's Phase 2 CLOVER WaM clinical trial of iopofosine I 131 to tre

    6/1/26 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

    Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)  Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026 Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy Data Expected Mid-year 2026 Company to Hold Webcast and Conference Call at 8:3

    5/14/26 7:15:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

    FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, May 14, 2026Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:63374Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website. About Cellectar Bios

    5/11/26 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Longcor Jarrod bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 74% to 20,451 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    5/11/26 8:07:18 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Caruso James V bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 75% to 20,318 units (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    5/11/26 8:05:44 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Neis John sold $732 worth of shares (198 units at $3.70) (SEC Form 4)

    4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

    12/16/25 6:00:11 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Cellectar Biosciences with a new price target

    Ladenburg Thalmann initiated coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $10.00

    5/15/26 8:17:35 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences upgraded by Maxim Group with a new price target

    Maxim Group upgraded Cellectar Biosciences from Hold to Buy and set a new price target of $10.00

    3/10/26 8:36:07 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target

    Ladenburg Thalmann resumed coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $13.00

    12/5/24 8:32:15 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Financials

    Live finance-specific insights

    View All

    Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

    FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, May 14, 2026Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:63374Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website. About Cellectar Bios

    5/11/26 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

    On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31

    3/4/26 7:15:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

    FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the full year ended December 31, 2025, and provide a corporate update on March 4, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Wednesday, March 4, 2026Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:08197Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website. About Cellectar B

    2/25/26 8:05:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLRB
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

    William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. "

    10/17/23 8:00:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

    ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

    3/27/23 4:05:00 PM ET
    $CLRB
    $MXCT
    $REXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Major Pharmaceuticals

    $CLRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

    SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

    11/14/24 4:47:59 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

    SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

    11/14/24 1:26:20 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

    SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

    8/14/24 7:15:55 PM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care